Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
About this item
Full title
Author / Creator
Pollack, Charles V , Reilly, Paul A , van Ryn, Joanne , Eikelboom, John W , Glund, Stephan , Bernstein, Richard A , Dubiel, Robert , Huisman, Menno V , Hylek, Elaine M , Kam, Chak-Wah , Kamphuisen, Pieter W , Kreuzer, Jörg , Levy, Jerrold H , Royle, Gordon , Sellke, Frank W , Stangier, Joachim , Steiner, Thorsten , Verhamme, Peter , Wang, Bushi , Young, Laura and Weitz, Jeffrey I
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Idarucizumab was 100% effective in reversing the anticoagulant effect of dabigatran among 300 patients with uncontrolled bleeding (median time to bleeding cessation, 2.5 hours) and among 200 patients who required an urgent procedure (median time to procedure initiation, 1.6 hours).
Alternative Titles
Full title
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Authors, Artists and Contributors
Author / Creator
Reilly, Paul A
van Ryn, Joanne
Eikelboom, John W
Glund, Stephan
Bernstein, Richard A
Dubiel, Robert
Huisman, Menno V
Hylek, Elaine M
Kam, Chak-Wah
Kamphuisen, Pieter W
Kreuzer, Jörg
Levy, Jerrold H
Royle, Gordon
Sellke, Frank W
Stangier, Joachim
Steiner, Thorsten
Verhamme, Peter
Wang, Bushi
Young, Laura
Weitz, Jeffrey I
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1925481601
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1925481601
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1707278
